Women’s Response in HIV Trial Affected by Dropouts, University of California, Los Angeles (UCLA) Reported

MedPageToday -- In an open-label study of treatment with darunavir (Prezista) and ritonavir (Norvir) for HIV infection, there were no significant differences between men and women in virologic response or adverse events, researchers found.